title: Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin.
abstract: This study investigated the effect of vasopressin on portal-systemic collaterals in portal hypertensive rats and the influence of nitric oxide (NO) and prostaglandin on the responsiveness of collateral vessels to vasopressin. The vascular responsiveness to graded concentrations of vasopressin was tested with or without the incubation of n(omega)-nitro-L-arginine (NNA) (100 micromol/L) and/or indomethacin (10 micromol/L) in perfused collateral vascular beds of rats with portal hypertension induced by partial portal vein ligation. In addition, concentration-response curves to vasopressin with incubation of a vasopressin V(1) receptor antagonist d(CH(2))(5)Tyr(Me) arginine vasopressin and concentration-response curves to a V(2) receptor agonist 1-desamino-8-D-arginine vasopressin were performed. Vasopressin significantly increased the perfusion pressure of collaterals, and this effect was suppressed by the addition of the V(1) receptor antagonist. Perfusion with the V(2) receptor agonist had no effect on the collaterals. Incubation with NNA, indomethacin, or both significantly potentiated the response of collaterals to vasopressin. In addition, the pressor response to vasopressin in the combination group was significantly higher than that in the NNA-alone group. The results show that vasopressin produces a direct vasoconstrictive effect on the portal-systemic collaterals of portal hypertensive rats. This effect is mediated by the vasopressin V(1,) but not V(2), receptors. The attenuation of the response to vasopressin by NO and prostaglandin suggest a function role of both mediators in the regulation of the portal-systemic collateral circulation in portal hypertensive rats.
authors.affiliation: Division of Gastroenterology, Department of Medicine, Veterans General Hospital, Taipei, Taiwan, Republic of China.
authors.forename: C C
authors.initials: CC
authors.lastname: Chan
authors.forename: F Y
authors.initials: FY
authors.lastname: Lee
authors.forename: S S
authors.initials: SS
authors.lastname: Wang
authors.forename: F Y
authors.initials: FY
authors.lastname: Chang
authors.forename: H C
authors.initials: HC
authors.lastname: Lin
authors.forename: C J
authors.initials: CJ
authors.lastname: Chu
authors.forename: C C
authors.initials: CC
authors.lastname: Tai
authors.forename: I N
authors.initials: IN
authors.lastname: Lai
authors.forename: S D
authors.initials: SD
authors.lastname: Lee
mesh_terms: D000818:Animals; D003097:Collateral Circulation / Q000187:drug effects*; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006975:Hypertension, Portal / Q000503:physiopathology*; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D009569:Nitric Oxide / Q000502:physiology*; D019335:Nitroarginine / Q000494:pharmacology; D011168:Portal System / Q000187:drug effects* / Q000503:physiopathology; D011453:Prostaglandins / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014667:Vasopressins / Q000494:pharmacology*
chemical_list: D011453:Prostaglandins; D014667:Vasopressins; D019335:Nitroarginine; D009569:Nitric Oxide; D003894:Deamino Arginine Vasopressin; D007213:Indomethacin